BIOADAPTIVES INC
For the period ended Dec 31, 2023. Filed Apr 10, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 10, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
We have employment agreements with our Chief Executive Officer, President and Chief Financial Officer, each of whom was to be compensated by stock grants accrued monthly based on current share prices or block grants during the period ended December 31, 2023. In consideration of the Company’s financial performance and lack of liquidity during this period, each of our officers waived compensation and we adjusted compensation accordingly.
The Company has no other executive compensation issues which would require the inclusion of other mandated table disclosures.
Director Compensation
Our directors’ compensation is wholly derived from their employment agreement as set out above.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.